rebounded to Covid positive and symptoms on day 11 of Covid so 4 days after completing course of Paxlovid; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (rebounded to Covid positive and symptoms on day 11 of Covid so 4 days after completing course of Paxlovid) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 020B21A) for COVID-19 vaccination.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment.    Previously administered products included for Product used for unknown indication: Morphine. Past adverse reactions to the above products included Allergy with Morphine.   On 22-Nov-2021 at 2:00 AM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Apr-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) at an unspecified dose. On 07-May-2022 at 1:00 PM, the patient experienced COVID-19 (rebounded to Covid positive and symptoms on day 11 of Covid so 4 days after completing course of Paxlovid). At the time of the report, COVID-19 (rebounded to Covid positive and symptoms on day 11 of Covid so 4 days after completing course of Paxlovid) was resolving. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 09-May-2022, SARS-CoV-2 test: positive (Positive) rebounded to Covid positive and symptoms on day 11 of Covid.         No concomitant medication was provided by the reporter.  It was reported that the patient was not taking any other medications/products within 2 weeks of starting COVID-19 treatment. Further device Date was reported as 18-May-2022.  No treatment medication was provided by the reporter.  Company comment.  This spontaneous case concerns a patient (unknown age and unknown gender) with no relevant medical history, who experienced the unexpected, non  serious of COVID  19, approximately 5 months after mRNA-1273 vaccine, reported as third dose of the COVID  19 immunization schedules; no information about previous vaccination schedule was provided. The report stated that the patient received treatment with Paxlovid for COVID  19 and rebounded to COVID positive and symptoms 11 days after the onset of the event (4 days after completing treatment with Paxlovid). No further details were provided for medical review. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Sender's Comments: This spontaneous case concerns a patient (unknown age and unknown gender) with no relevant medical history, who experienced the unexpected, non  serious of COVID  19, approximately 5 months after mRNA-1273 vaccine, reported as third dose of the COVID  19 immunization schedules; no information about previous vaccination schedule was provided. The report stated that the patient received treatment with Paxlovid for COVID  19 and rebounded to COVID positive and symptoms 11 days after the onset of the event (4 days after completing treatment with Paxlovid). No further details were provided for medical review. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.